To examine PD-L1 as a prognostic marker in patients with pT3 and pT4 colon cancer, highlighting its potential impact on treatment decisions.
Key Findings:
PD-L1 expression correlates with worse overall survival in pT3 and pT4 colon cancer, suggesting a need for targeted therapies.
Different scoring methods (TPS, ICS, CPS) yield varying prognostic implications, indicating the importance of standardized evaluation.
Mismatch repair status influences the relationship between PD-L1 expression and survival outcomes, highlighting the need for personalized treatment approaches.
Interpretation:
The study suggests that PD-L1 expression is a significant prognostic marker in colon cancer, with the method of evaluation critically impacting the interpretation of results.
Limitations:
Retrospective design may introduce bias, limiting the generalizability of the findings.
Lack of standardized PD-L1 evaluation guidelines in colorectal cancer complicates the interpretation of results.
Conclusion:
Standardized methods for PD-L1 evaluation are essential to accurately assess its prognostic value in colorectal cancer and guide treatment strategies.
by Dea Natalie Munch Jepsen, Marianne Bøgevang Jensen, Astrid Louise Bjørn Bennedsen, Trine Lønbo Grantzau, Thomas Thiilmark Eriksen, Jens Ole Eriksen, Michael Bzorek, Ismail Gögenur, Anne-Marie Kanstrup Fiehn
